| 3.23 -0.07 (-2.12%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.14 | 1-year : | 4.84 |
| Resists | First : | 3.54 | Second : | 4.14 |
| Pivot price | 3.24  |
|||
| Supports | First : | 3.11 | Second : | 2.83 |
| MAs | MA(5) : | 3.28 |
MA(20) : | 3.19 |
| MA(100) : | 2.96 |
MA(250) : | 3.69 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 48.6 |
D(3) : | 54.5 |
| RSI | RSI(14): 53.4 |
|||
| 52-week | High : | 6.44 | Low : | 2.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ALT ] has closed above bottom band by 46.8%. Bollinger Bands are 33.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.31 - 3.33 | 3.33 - 3.35 |
| Low: | 3.15 - 3.18 | 3.18 - 3.2 |
| Close: | 3.19 - 3.23 | 3.23 - 3.26 |
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Fri, 11 Sep 2026
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? - Yahoo Finance
Mon, 07 Sep 2026
Altimmune’s (ALT) Three Liver Trials Move Forward At Once - Yahoo Finance
Thu, 03 Sep 2026
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Thu, 13 Aug 2026
Altimmune: Pemvidutide Performs, But A Long Wait Ahead (NASDAQ:ALT) - Seeking Alpha
Wed, 12 Aug 2026
Altimmune Announces Second Quarter 2026 Financial Results and Business Update - Yahoo Finance
Tue, 28 Jul 2026
Altimmune rises as GLP-1 cuts drinking in mid-stage trial - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 195 (M) |
| Held by Insiders | 1.6439e+008 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 48,240 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.863e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -318 % |
| Return on Assets (ttm) | 493.5 % |
| Return on Equity (ttm) | -17.3 % |
| Qtrly Rev. Growth | 31000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -160.39 |
| EBITDA (p.s.) | -3.705e+008 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -77 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 32.6 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.23 |
| Dividend | 0 |
| Forward Dividend | 5.097e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|